Stapokibart not checked

Keymed Biosciences Co.Ltd · CM310 · IL-4Rα monoclonal antibody

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 3 trial completes
Trials
8 active
30 in total
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
Tested for
Atopic Dermatitis (3 trials), Seasonal Allergic Rhinitis (SAR) (2 trials), Bullous Pemphigoid (BP), Chronic Obstructive Pulmonary Disease, Moderate to Severe Asthma
Main trialPhase 3
“This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with moderate-to-severe atopic dermatitis.”In the company’s words, NCT06956196 on ClinicalTrials.gov
Other names
Stapokibatrt · CM310 · IL-4Rα monoclonal antibody

Other drugs for Atopic Dermatitis

All 90 drugs for Atopic Dermatitis

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials30

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting May 2026 Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
Phase 3Active, not recruiting 30 Aug 2026 Study of CM310 in Adolescent Subjects With Atopic Dermatis
Phase 3Recruiting Dec 2026 Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis
Phase 3Not yet recruiting Feb 2027 A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
Phase 3Not yet recruiting 27 Mar 2028 Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
Phase 2/3Not yet recruiting 29 Apr 2032 A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 2/3Recruiting May 2032 A Study of CM310 in Subjects With Moderate to Severe Asthma
Phase 2Not yet recruiting Oct 2026 Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
Phase 3Completed 31 Oct 2023 A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
Phase 3Completed 4 Dec 2023 Study of CM310 in Subjects With Allergic Rhinitis
Phase 3Completed 25 Jun 2024 A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-2)
Phase 3Completed 23 Jan 2025 Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis
Phase 3Completed 11 Feb 2026 Study on the Treatment of Prurigo Nodularis With Stapokibart Injection
Phase 2Completed 8 Nov 2021 Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
Phase 2Completed 18 Mar 2022 Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1)
Phase 2Completed 3 Feb 2023 The Study of CM310 in Patients With Atopic Dermatitis
Phase 2Completed 28 Jul 2023 A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
Phase 2Completed 13 Sep 2023 A Study of CM310 in Subjects With Moderate to Severe Asthma
Phase 2Completed 10 Dec 2023 Study of CM310 in Patients With Allergic Rhinitis
Phase 2Completed 31 Jan 2024 The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Phase 2Unknown 1 Mar 2024 A Study of CM310 in Subjects With Chronic Pruritus
Phase 2Completed 18 Jul 2024 Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis
Phase 2Unknown 30 Mar 2025 Study of CM310 in Subjects With Seasonal Allergic Rhinitis
Phase 2Unknown 30 Oct 2025 Study of Stapokibart Injection in Patients With Allergic Rhinitis
Phase 2Completed 26 Nov 2025 A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
Phase 1/2Completed 22 Jan 2021 Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
Phase 1/2Completed 4 Jul 2024 Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis
Phase 1Completed 13 Jan 2020 Study of CM310 in Healthy Subjects
Phase 1Completed 26 Jul 2023 Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310
Phase 1Unknown 30 Apr 2025 Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Stapokibart

Following is part of Solo: you see every change to Stapokibart the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in